Activaero has appointed Ulrich Dauer as Chief Strategy Officer
He joins at a time when the Company is progressing fast towards the filing for approval of its lead product for the treatment of severe asthma, FAVOLIR, and will be responsible for corporate development strategy and the implementation of the respective financing needed.
Share
Download our apps
Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.
Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.